蘆平曲韋

蘆平曲韋
臨床資料
商品名（英語：Drug nomenclature）	Rupintrivir
法律規範狀態
法律規範	美：Investigational drug;
識別資訊
	IUPAC命名法 ethyl (E,4S)-4-[[(2R,5S)-2-[(4-fluorophenyl)methyl]-6-methyl-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-4-oxoheptanoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate; ;
CAS編號	223537-30-2
PubChem CID	6440352;
DrugBank	05102;
ChemSpider	4944627;
UNII	RGE5K1Q5QW;
KEGG	D05776;
ChEMBL	ChEMBL20210;
化學資訊
化學式	C31H39FN4O7
莫耳質量	598.7
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC2=CC=C(C=C2)F)CC(=O)[C@H](C(C)C)NC(=O)C3=NOC(=C3)C;
	InChI InChI=1S/C31H39FN4O7/c1-5-42-27(38)11-10-24(16-21-12-13-33-29(21)39)34-30(40)22(15-20-6-8-23(32)9-7-20)17-26(37)28(18(2)3)35-31(41)25-14-19(4)43-36-25/h6-11,14,18,21-22,24,28H,5,12-13,15-17H2,1-4H3,(H,33,39)(H,34,40)(H,35,41)/b11-10+/t21-,22+,24+,28-/m0/s1; Key:CAYJBRBGZBCZKO-BHGBQCOSSA-N;

蘆平曲韋（英語：Rupintrivir，也叫AG-7088、Rupinavir）是一種擬肽抗病毒藥物，可作為小核糖核酸病毒3C蛋白酶和3C樣蛋白酶抑制劑。^[1]^[2]^[3]它是為治療鼻病毒而開發的，^[4]^[5]隨後被研究用於治療其他病毒性疾病，包括由小核糖核酸病毒引起的疾病、^[6]^[7]諾如病毒、^[8]和冠狀病毒，例如SARS和COVID-19。^[9]^[10]

參見

參考文獻

^ Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Journal of Medicinal Chemistry. April 1999, 42 (7): 1213–24. PMID 10197965. doi:10.1021/jm9805384.
^ Santos MM, Moreira R. Michael acceptors as cysteine protease inhibitors. Mini Reviews in Medicinal Chemistry. October 2007, 7 (10): 1040–50. PMID 17979807. doi:10.2174/138955707782110105.
^ Yuan S, Fan K, Chen Z, Sun Y, Hou H, Zhu L. Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design. Virologica Sinica. February 2020, 35 (4): 445–454. PMC 7462945 . PMID 32103448. doi:10.1007/s12250-020-00196-4.
^ Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy. October 1999, 43 (10): 2444–50. PMC 89498 . PMID 10508022. doi:10.1128/AAC.43.10.2444.
^ Jensen LM, Walker EJ, Jans DA, Ghildyal R. Proteases of human rhinovirus: role in infection. Rhinoviruses. Methods in Molecular Biology 1221. 2015: 129–41. ISBN 978-1-4939-1570-5. PMID 25261311. doi:10.1007/978-1-4939-1571-2_10.
^ Barnard DL. Current status of anti-picornavirus therapies. Current Pharmaceutical Design. 2006, 12 (11): 1379–90. PMID 16611122. doi:10.2174/138161206776361129.
^ De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Medicinal Research Reviews. November 2008, 28 (6): 823–84. PMID 18381747. S2CID 1575335. doi:10.1002/med.20125.
^ Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrobial Agents and Chemotherapy. August 2014, 58 (8): 4675–81. PMC 4136040 . PMID 24890597. doi:10.1128/AAC.02546-13.
^ Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. June 2003, 300 (5626): 1763–7. Bibcode:2003Sci...300.1763A. PMID 12746549. doi:10.1126/science.1085658 .
^ Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020, 6 (3): 315–331. PMC 7094090 . PMID 32226821. doi:10.1021/acscentsci.0c00272 .

[1] Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Journal of Medicinal Chemistry. April 1999, 42 (7): 1213–24. PMID 10197965. doi:10.1021/jm9805384.

[2] Santos MM, Moreira R. Michael acceptors as cysteine protease inhibitors. Mini Reviews in Medicinal Chemistry. October 2007, 7 (10): 1040–50. PMID 17979807. doi:10.2174/138955707782110105.

[3] Yuan S, Fan K, Chen Z, Sun Y, Hou H, Zhu L. Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design. Virologica Sinica. February 2020, 35 (4): 445–454. PMC 7462945 . PMID 32103448. doi:10.1007/s12250-020-00196-4.

[4] Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, et al. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy. October 1999, 43 (10): 2444–50. PMC 89498 . PMID 10508022. doi:10.1128/AAC.43.10.2444.

[5] Jensen LM, Walker EJ, Jans DA, Ghildyal R. Proteases of human rhinovirus: role in infection. Rhinoviruses. Methods in Molecular Biology 1221. 2015: 129–41. ISBN 978-1-4939-1570-5. PMID 25261311. doi:10.1007/978-1-4939-1571-2_10.

[6] Barnard DL. Current status of anti-picornavirus therapies. Current Pharmaceutical Design. 2006, 12 (11): 1379–90. PMID 16611122. doi:10.2174/138161206776361129.

[7] De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Medicinal Research Reviews. November 2008, 28 (6): 823–84. PMID 18381747. S2CID 1575335. doi:10.1002/med.20125.

[8] Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrobial Agents and Chemotherapy. August 2014, 58 (8): 4675–81. PMC 4136040 . PMID 24890597. doi:10.1128/AAC.02546-13.

[9] Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. June 2003, 300 (5626): 1763–7. Bibcode:2003Sci...300.1763A. PMID 12746549. doi:10.1126/science.1085658 .

[10] Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020, 6 (3): 315–331. PMC 7094090 . PMID 32226821. doi:10.1021/acscentsci.0c00272 .

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]